Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W
PLoS One. 2007 2 (8): e810

PMID: 17726540 · PMCID: PMC1950079 · DOI:10.1371/journal.pone.0000810

BACKGROUND - The EGFR T790M mutation confers acquired resistance to kinase inhibitors in human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and may confer genetic susceptibility to lung cancer.

METHODOLOGY/PRINCIPAL FINDINGS - To study further its role in lung tumorigenesis, we developed mice with inducible expression in type II pneumocytes of EGFR(T790M) alone or together with a drug-sensitive L858R mutation. Both transgenic lines develop lung adenocarcinomas that require mutant EGFR for tumor maintenance but are resistant to an EGFR kinase inhibitor. EGFR(L858R+T790M)-driven tumors are transiently targeted by hsp90 inhibition. Notably, EGFR(T790M)-expressing animals develop tumors with longer latency than EGFR(L858R+T790M)-bearing mice and in the absence of additional kinase domain mutations.

CONCLUSIONS/SIGNIFICANCE - These new mouse models of mutant EGFR-dependent lung adenocarcinomas provide insight into clinical observations. The models should also be useful for developing improved therapies for patients with lung cancers harboring EGFR(T790M) alone or in conjunction with drug-sensitive EGFR kinase domain mutations.

MeSH Terms (14)

Animals Antineoplastic Agents Benzoquinones Disease Models, Animal Drug Resistance, Neoplasm ErbB Receptors Genotype HSP90 Heat-Shock Proteins Lactams, Macrocyclic Lung Neoplasms Mice Mice, Transgenic Mutation Protein Kinase Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities: